Three cases
of lymphoma were reported among patients who
received tofacitinib. As previously reported and
as seen in this study, tofacitinib was associated
with decreases in neutrophil and lymphocyte
counts and increases in lipid, aminotransferase,
and creatinine levels. Although the clinical relevance
of the lipid changes is unclear, monitoring
of lipids and, when needed, appropriate intervention,
including the use of lipid-lowering
agents, may be warranted.31 The mechanism
behind the increase in creatinine levels is unknown,
but it may involve the effects of tofacitinib
on inflammation.3